Abivax ABVX
NASDAQ ABVX
$93.49 +0.90 (+0.97%)
At close: Oct 21, 2026 · 4:00 PM EDT

Abivax (ABVX) Enterprise Value (2023 - 2026)

Updated

Abivax's Enterprise Value was $10.01 billion in Q2 2026, compared with $409.34 million a year earlier and up 22.4% from the prior quarter.

Analysis

Abivax (ABVX) Enterprise Value (2023 - 2026) Analysis & Trends

On a trailing twelve-month basis, Abivax's Enterprise Value was $8.14 billion through Jun 30, 2026; for FY2025, it came in at $10 billion.

  • In earlier years, Enterprise Value was $301.2 million in FY2024 (+72.8%) and $174.35 million in FY2023.
  • The Q2 2026 figure marks the highest quarterly Enterprise Value in data going back to Q4 2023.
  • Per Business Quant data, ABVX's Enterprise Value in the three quarters before Q2 2026 was $8.18 billion (Q1 2026), $9.98 billion (Q4 2025) and $4.68 billion (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn
10 Abivax 6.50 Bn 4.14 Bn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 10.00 Bn
Mar 31, 2026 8.19 Bn
Dec 31, 2025 9.96 Bn
Sep 30, 2025 4.68 Bn
Jun 30, 2025 403.73 Mn
Mar 31, 2025 275.64 Mn
Dec 31, 2024 305.77 Mn
Sep 30, 2024 523.38 Mn
Jun 30, 2024 580.16 Mn
Mar 31, 2024 639.08 Mn
Dec 31, 2023 384.32 Mn
API Access

Abivax Enterprise Value API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=enterprise-value&ticker=ABVX&period=max&api_key=YOUR_API_KEY